Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries.
Business & Industry
- Sanofi and GSK selected for Operation Warp Speed to supply United States government with 100 million doses of COVID-19 vaccine
- Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
- Pfizer and BioNTech to supply Japan with 120 million doses of their BNT162 mRNA-based vaccine candidate
- Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal Phase 2/3 global study
- Pfizer and BioNTech announce an agreement with U.S. Government for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2
Research & Development
- COVID-19: Immune system derails
- UK and US healthcare workers report higher rates of COVID-19 compared to general population in early pandemic period
- Single-shot COVID-19 vaccine protects non-human primates
- Immunoprotein impairs Sars-Cov-2
- Experimental COVID-19 vaccine protects upper and lower airways in nonhuman primates
- Another mRNA-based vaccine candidate protects animals against SARS-CoV-2
- Neutralizing antibodies isolated from COVID-19 patients may suppress virus
Conferences & Events
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
- COVID-19 vaccine innovation could dramatically speed up worldwide production
- Wearable Injectors and Connected Devices Conference 2020
- Preparing for the new world of drug safety: Embracing cloud and AI
- Pre-filled Syringes San Francisco Conference 2020
- Oligonucleotide Therapeutics and Delivery Conference 2020
- Pre-Filled Syringes West Coast 2021
Regulatory Affairs
- FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines
- FDA announces first of its kind pilot program to communicate patient reported outcomes from cancer clinical trials
- FDA revokes emergency use authorization for chloroquine and hydroxychloroquine
- Global regulators commit to cooperate on observational research in the context of COVID-19
- FDA takes new actions to accelerate development of novel prevention, treatment options for COVID-19